354 related articles for article (PubMed ID: 23647051)
41. Cell cycle molecular targets in novel anticancer drug discovery.
Buolamwini JK
Curr Pharm Des; 2000 Mar; 6(4):379-92. PubMed ID: 10788588
[TBL] [Abstract][Full Text] [Related]
42. Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines.
Eguchi T; Itadani H; Shimomura T; Kawanishi N; Hirai H; Kotani H
Mol Cancer Ther; 2009 Jun; 8(6):1460-72. PubMed ID: 19509251
[TBL] [Abstract][Full Text] [Related]
43. Complexities in the development of cyclin-dependent kinase inhibitor drugs.
Sausville EA
Trends Mol Med; 2002; 8(4 Suppl):S32-7. PubMed ID: 11927285
[TBL] [Abstract][Full Text] [Related]
44. Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein.
Wesierska-Gadek J; Schmid G
Expert Opin Investig Drugs; 2006 Jan; 15(1):23-38. PubMed ID: 16370931
[TBL] [Abstract][Full Text] [Related]
45. Naturally Sourced CDK Inhibitors and Current Trends in Structure-Based Synthetic Anticancer Drug Design by Crystallography.
Nandi S; Dey R; Dey S; Samadder A; Saxena AK
Anticancer Agents Med Chem; 2022; 22(3):485-498. PubMed ID: 34503422
[TBL] [Abstract][Full Text] [Related]
46. CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets.
Kohlmeyer JL; Gordon DJ; Tanas MR; Monga V; Dodd RD; Quelle DE
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32344731
[TBL] [Abstract][Full Text] [Related]
47. Cyclin-dependent kinase inhibitors: novel anticancer agents.
Mani S; Wang C; Wu K; Francis R; Pestell R
Expert Opin Investig Drugs; 2000 Aug; 9(8):1849-70. PubMed ID: 11060782
[TBL] [Abstract][Full Text] [Related]
48. Cell death induction in resting lymphocytes by pan-Cdk inhibitor, but not by Cdk4/6 selective inhibitor.
Kobayashi M; Takahashi-Suzuki I; Shimomura T; Iwasawa Y; Hirai H
Invest New Drugs; 2011 Oct; 29(5):921-31. PubMed ID: 20524038
[TBL] [Abstract][Full Text] [Related]
49. Rhabdoid tumor growth is inhibited by flavopiridol.
Smith ME; Cimica V; Chinni S; Challagulla K; Mani S; Kalpana GV
Clin Cancer Res; 2008 Jan; 14(2):523-32. PubMed ID: 18223228
[TBL] [Abstract][Full Text] [Related]
50. A novel class of cyclin-dependent kinase inhibitors identified by molecular docking act through a unique mechanism.
Corsino P; Horenstein N; Ostrov D; Rowe T; Law M; Barrett A; Aslanidi G; Cress WD; Law B
J Biol Chem; 2009 Oct; 284(43):29945-55. PubMed ID: 19710018
[TBL] [Abstract][Full Text] [Related]
51. Ibulocydine is a novel prodrug Cdk inhibitor that effectively induces apoptosis in hepatocellular carcinoma cells.
Cho SJ; Kim YJ; Surh YJ; Kim BM; Lee SK
J Biol Chem; 2011 Jun; 286(22):19662-71. PubMed ID: 21478145
[TBL] [Abstract][Full Text] [Related]
52. Synthesis, in vitro anticancer activity and in silico studies of certain pyrazole-based derivatives as potential inhibitors of cyclin dependent kinases (CDKs).
Mohammed EZ; Mahmoud WR; George RF; Hassan GS; Omar FA; Georgey HH
Bioorg Chem; 2021 Nov; 116():105347. PubMed ID: 34555628
[TBL] [Abstract][Full Text] [Related]
53. The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer.
Ding L; Cao J; Lin W; Chen H; Xiong X; Ao H; Yu M; Lin J; Cui Q
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183020
[TBL] [Abstract][Full Text] [Related]
54. The roles and therapeutic potential of cyclin-dependent kinases (CDKs) in sarcoma.
Liao Y; Feng Y; Shen J; Hornicek FJ; Duan Z
Cancer Metastasis Rev; 2016 Jun; 35(2):151-63. PubMed ID: 26669603
[TBL] [Abstract][Full Text] [Related]
55. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
[TBL] [Abstract][Full Text] [Related]
56. Molecules inducing specific cyclin-dependent kinase degradation and their possible use in cancer therapy.
Zheng M; Zhang XY; Chen W; Xia F; Yang H; Yuan K; Yang P
Future Med Chem; 2024 Feb; 16(4):369-388. PubMed ID: 38288571
[TBL] [Abstract][Full Text] [Related]
57. Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7.
Hu S; Marineau JJ; Rajagopal N; Hamman KB; Choi YJ; Schmidt DR; Ke N; Johannessen L; Bradley MJ; Orlando DA; Alnemy SR; Ren Y; Ciblat S; Winter DK; Kabro A; Sprott KT; Hodgson JG; Fritz CC; Carulli JP; di Tomaso E; Olson ER
Cancer Res; 2019 Jul; 79(13):3479-3491. PubMed ID: 31064851
[TBL] [Abstract][Full Text] [Related]
58. Development of a cyclin-dependent kinase inhibitor devoid of ABC transporter-dependent drug resistance.
Kaliszczak M; Patel H; Kroll SH; Carroll L; Smith G; Delaney S; Heathcote DA; Bondke A; Fuchter MJ; Coombes RC; Barrett AG; Ali S; Aboagye EO
Br J Cancer; 2013 Oct; 109(9):2356-67. PubMed ID: 24071597
[TBL] [Abstract][Full Text] [Related]
59. Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapy.
Tan AR; Swain SM
Semin Oncol; 2002 Jun; 29(3 Suppl 11):77-85. PubMed ID: 12138401
[TBL] [Abstract][Full Text] [Related]
60. Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications.
McMillin DW; Delmore J; Negri J; Buon L; Jacobs HM; Laubach J; Jakubikova J; Ooi M; Hayden P; Schlossman R; Munshi NC; Lengauer C; Richardson PG; Anderson KC; Mitsiades CS
Br J Haematol; 2011 Feb; 152(4):420-32. PubMed ID: 21223249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
